This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.
Study Type
OBSERVATIONAL
Enrollment
100
The Chinese University of Hong Kong
Hong Kong, Hong Kong
RECRUITINGBiobank construction
Recruit patients and collect the required biological samples (i.e. tumor tissues, blood and ascites samples) for biobank construction.
Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Detection of noval therapeutic targets for treating gastric cancer cancer with metastases.
Biological samples (i.e. tissue, blood and ascites samples) collected from enrolled patients will be used in genome and transcriptome analysis using next generation sequencing, DNA mutation detection using digital PCR and mass spectrometry-based proteomic.
Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Organoid culture for drug sensitivity assay
Gastric tumor tissues are collected from enrolled patients to establish patient-derived organoids and subject to drug sensitivity assay. The choice of drugs will depend on the molecular analysis results and will be advised by oncologists.
Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.
Clinical Outcome - Overall survival
Patients' overall survival will also be recorded.
Time frame: through study completion, an average of 5 year
Clinical Outcome - Progression-free survival
Patients' progression-free survival will also be recorded.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: through study completion, an average of 5 year
Clinical Outcome - Karnofsky Score
Karnofsky Score for measuring quality of life will be recorded
Time frame: At baseline measurement
Clinical Outcome - Time point of metastasis
Patients' time point of metastasis, whether it is synchronous or metachronous will be recorded
Time frame: Recruitment till death or 5 year
Clinical Outcome - Number of previous chemotherapy/ target therapy/ immunotherapy
Number of previous chemotherapy/ target therapy/ immunotherapy received by the patients will be recorded
Time frame: Measured and asked at baseline
Clinical Outcome - Presence of ascites
Presence of ascites on recruited patients will be recorded
Time frame: Recruitment till death or 5 year
Clinical Outcome - Cancer Restaging
Stage of cancer will be recorded and determined with CT/PETCT scan
Time frame: Post-treatment till death or 5 year